Gabriel Sermon
Medical · Castle Dale, UTNPI 1639299282
Payments from drug & device makers
Across 120 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$814
- AstraZeneca$425
- Lilly USA, LLC$154
- Mylan Specialty L.p.$126
- Boehringer Ingelheim$96
- Myriad Women's Health, Inc.$71
- plus $439 from 15 others
What the payments were for
- Food & beverage$2,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $814 |
| AstraZeneca | 25 | $425 |
| Lilly USA, LLC | 8 | $154 |
| Mylan Specialty L.p. | 7 | $126 |
| Boehringer Ingelheim | 6 | $96 |
| Myriad Women's Health, Inc. | 1 | $71 |
| Pfizer | 4 | $68 |
| Novo Nordisk | 4 | $66 |
| Amgen | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Novartis | 1 | $24 |
| Abbott | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Organon | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$2,124 in reported general payments places this provider in the 65th percentile of 263 medical providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 34 | $31,993 |
| OzempicSemaglutide | 19 | $30,273 |
| VraylarCariprazine Hcl | 16 | $21,843 |
| JardianceEmpagliflozin | 17 | $16,986 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,661 |
| MyrbetriqMirabegron | 16 | $10,513 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,054 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,229 |
| Dexlansoprazole DrDexlansoprazole | 27 | $5,489 |
| DayvigoLemborexant | 13 | $4,444 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,085 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,429 |
| Levothyroxine Sodium | 107 | $1,460 |
| Tramadol Hcl | 87 | $1,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $154 | $31,99334 claims |
| Novo NordiskOzempic | $66 | $30,27319 claims |
| AbbVieVraylar, Synthroid | $814 | $22,37928 claims |
| Boehringer IngelheimJardiance | $96 | $16,98617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 263 medical providers in Utah.
Other medical in Castle Dale
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$65K
- Val WarnerLayton$51K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
- Mark UdySt George$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.